Found 13 articles
Blacksmith Medicines, Inc. and Zoetis announced a collaboration to discover and develop novel antibiotics for animal health.
Blacksmith Medicines, Inc. announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.
Blacksmith Medicines Announces Merger With Forge Therapeutics to Create Leading Company Developing Medicines Targeting Metalloenzymes
Blacksmith Medicines, Inc., and Forge Therapeutics, announce that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.
Blacksmith Medicines announced on Friday it had secured a multimillion dollar seed funding deal from Eli Lilly and has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets.
Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly).
Forge Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office Covering Novel Chemistry Targeting LpxC For The Treatment Of Gram-Negative Bacterial Infections
Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the treatment of Gram-negative bacterial infections.
Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes.
Presentation will focus on Forge's novel chemistry platform, BLACKSMITH, and its therapeutic applications
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
Forge Therapeutics, Inc. announced today that it has received a second CARB-X award for developing a novel antibacterial therapeutic agent.
Forge Achieves CARB-X Milestone To Advance Its LpxC Antibiotic To Treat Infections Caused By The World's Deadliest 'Superbugs'
-Technical milestone achievement and program advancement from initial round of 'Powered by CARB-X' products-
Forge Announces Oral Presentation On Development Of Novel Antibiotics At The 28th Annual ECCMID Meeting
Forge Therapeutics, Inc. announced that David Puerta, Ph.D., Forge's COO and VP of Discovery, will discuss Forge's emerging initiatives in antibacterial R&D in an oral presentation at the 28th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting being held April 21-24, 2018 in Madrid, Spain.
Forge Therapeutics and Collaborators From Evotec and USC Present New Efficacy Data At 2017 Keystone Symposia Conference
Forge announced new efficacy data today on Forge's LpxC antibiotic program at the 2017 Keystone Symposia Conference "Antimicrobials and Resistance: Opportunities and Challenges" during an oral presentation and a poster session.
Forge & Evotec Expand Strategic Alliance With Launch Of BLACKSMITH Platform To Discover Novel Metalloenzyme Inhibitors Across Broad Therapeutic Areas
Forge announced today that the companies have expanded their existing strategic alliance and launched the BLACKSMITH platform to discover a broader range of therapeutics targeting metalloenzymes.